A phase III clinical trial of fixed dose combination Cefepime / AAI101
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2018
At a glance
- Drugs AAI101/cefepime (Primary)
- Indications Gram-negative infections
- Focus Therapeutic Use
- 23 Aug 2018 According to an Allecra Therapeutics media release, trial will be executed in 19 countries and in 114 trial sites, with more than 1,000 patients involved.
- 23 Aug 2018 According to an Allecra Therapeutics media release, company is ready to commence this study.
- 16 Feb 2018 New trial record